DNLI
Denali Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.38
+9.92%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 33.63x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 3.70x
- Price / sales
- 160.28x
- Price / cash flow
- -7.72x
Enterprise value
- Enterprise value
- $2.9B
- EV / sales
- 137.29x
- EV / EBITDA
- -5.85x
- EV / EBIT
- -5.52x
- Market cap
- $3.4B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Sep 1, 2026